research Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer: Impact of CDK4/6 Inhibitors on the Current Treatment Paradigm
CDK4/6 inhibitors have improved treatment outcomes for certain advanced breast cancer patients.
Search
forLearn
0 / 0 results — no results
Research
5 / 175 results 
research Safety and Patient-Reported Outcomes in Patients With Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer Treated With CDK4/6 Inhibitors in China: A Cross-Sectional Study
Dalpiciclib is the safest and most satisfying CDK4/6 inhibitor for advanced breast cancer patients in China.
research Retrospective Cohort Study of CDK4/6-Inhibitor-Induced Alopecia in Patients With Breast Cancer
CDK4/6 inhibitors may cause hair loss in breast cancer patients.
research CDK4/6 Plus Aromatase Inhibitor-Induced Alopecia in Breast Cancer Patients
Some breast cancer treatments cause hair loss similar to male pattern baldness, which can be improved with minoxidil.
research Fatigue, Alopecia, and Stomatitis Among Patients With Breast Cancer Receiving Cyclin-Dependent Kinase 4 and 6 Inhibitors: A Systematic Review and Meta-Analysis
Breast cancer patients taking CDK4/6 inhibitors are more likely to experience fatigue, hair loss, and mouth sores.
Community Join
0 / 0 results — no results